Cargando…

Development and validation of a predictive model to guide the use of plerixafor in pediatric population

Plerixafor, a CXCR4 receptor antagonist, reduces the binding and chemotaxis of hematopoietic stem cells to the bone marrow stroma, resulting in predictable peak of cluster of differentiation 34(+) (CD34(+)) cells in the peripheral blood (PB) approximately 10 h after its administration. We developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sebastien, Bernard, Cheverton, Peter, Magnin, Catherine, Aouni, Jihane, Castan, Remi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715428/ https://www.ncbi.nlm.nih.gov/pubmed/36163427 http://dx.doi.org/10.1038/s41409-022-01831-2

Ejemplares similares

Plerixafor
por: Slater, Susan
Publicado: (2012)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin’s lymphoma weighing ≤70 kg
por: Kuruvilla, John, et al.
Publicado: (2018)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
por: Sison, Edward Allan R., et al.
Publicado: (2014)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Cómo funcionan las marcas
por: Cheverton, Peter
Publicado: (2007)

Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)
por: Morland, Bruce, et al.
Publicado: (2020)

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers
por: Visram, Alissa, et al.
Publicado: (2018)

Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
por: Valentini, Caterina Giovanna, et al.
Publicado: (2023)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
por: Sureda, Anna, et al.
Publicado: (2019)

Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment
por: Hong, Kyung Taek, et al.
Publicado: (2012)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor
por: Uchida, Naoya, et al.
Publicado: (2020)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
por: McDermott, David H., et al.
Publicado: (2023)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
por: Agarwal, Rishi, et al.
Publicado: (2012)

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
por: Clark, R E, et al.
Publicado: (2014)

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India
por: Das, Soumya, et al.
Publicado: (2022)

Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
por: Corbingi, Andrea, et al.
Publicado: (2021)

A Machine Learning Classifier Improves Mortality Prediction Compared With Pediatric Logistic Organ Dysfunction-2 Score: Model Development and Validation
por: Prince, Remi D., et al.
Publicado: (2021)

Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
por: Avramova, Boryana E, et al.
Publicado: (2011)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fqms6omlma0v427h603macss3v